Product characterisation key to successful CAR T therapies, Autolus

By Dan Stanton contact

- Last updated on GMT

GettyImages/Meletios Verras
GettyImages/Meletios Verras

Related tags: Gene, Cell therapy manufacturing & gene therapy congress

CAR T-cell understanding must come before the process design if such therapies are ever going to be accessible to a larger patient population, says Autolus.

Last year saw the US approvals of the first two chimeric antigen receptor (CAR) T-cell therapies: Novartis’ Kymriah (tisagenlecleucel) and Kite/Gilead’s Yescarta (axicabtagene ciloleucel).

Many, including the US FDA, heralded this as the beginning of “a new frontier in medical innovation”​but patient groups have hit out at their list prices: $475,000 (€389,000) for the single treatment of Kymriah and $373,000 for Yescarta.

And speaking at last month’s Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam, Jim Faulkner, SVP and head of manufacturing at UK-based CAR T-cell therapy developer Autolus, said it was imperative to reduce the costs to allow such therapies to succeed.

“We’ve raised the promise of cell therapy and shown what can be done, yet behind that are price tags that are eye watering and issues around our ability to supply the market and actually deliver these products,”​ he told delegates.

“It is absolutely imperative that we take what is now beyond a promise into something that’s a reality for patients.”

Understanding the biology

The CAR T production experience so far has been variable, difficult to scale and expensive, “so we are not in a great place right now,”​ he added. Ideally, companies need to bring about a good commercial process consisting of a cheap, robust, predictable and scalable platform making consistent product.

“At the heart of these products are T Cells, and understanding these T Cells – what they do, how they behave ex vivo, how you can manipulate them – is absolutely critical for you to be able to produce a quality product.”

And while he said there are other factors which will aid successful CAR T commercialisation and reduced prices – having the right safety profile, clinical efficacy, facility and logistics network – he said understanding the product and the biology is core.

Without adequate characterisation, it is not possible to know what the product is, how process changes impact the product, and how to monitor and control the process parameters, he argued.

“If you do not understand what the product is that you are trying to make, you cannot design the process to try and make that product. It’s a very circular argument.”

Related news

Show more

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more